Allon Therapeutics Inc. (NPC-TSXV)
Interview with: Frederick Gordon McCauley, President and Secretary
Business News, Financial News, Stocks, Money & Investment Ideas, CEO Interview
and Information on their neuroprotective therapeutic molecules for treating neurodegeneration diseases and trauma.

Cover Story

CEOCFO Current Issue

Cover Story Archives

Private Equity Review

CEOCFO Interview Index

Future Features

Analyst Interviews

Corporate Financials

Contact & Ordering

This is a printer friendly page!

Allon Therapeutics is known as the Neuro Protection Company because their technology has shown broad efficacy against a number of applications such as Alzheimers, Multiple Schlerosis, ALS, or acute indications like stroke, or traumatic brain injury



Healthcare
Biotechnology
(NPC-TSXV)

Allon Therapeutics Inc.




Gordon McCauley
President and Secretary

Interview conducted by:
Lynn Fosse, Senior Editor
CEOCFOinterviews.com
June 2, 2005

To order the complete June 2, 2005 Issue of CEOCFOinterviews.com left click below for our secure forms:

Purchase NOW!

There is a $5.00 charge for each current issue!
You will be emailed your Current Issue and an invoice for Credit Card payment!

disclaimers

Any reproduction or further distribution of this article without the express written consent of CEOCFOinterviews.com is prohibited.

"NPC is about some of the larger diseases like Alzheimer's, Multiple Sclerosis, ALS, or acute indications like stroke, or traumatic brain injury and neuropathy associated with certain diseases like cancer and diabetes. It is a broad category. We deliberately called ourselves the Neuro Protection Company because this technology has shown broad efficacy against a number of those applications.  We think it is a place, where a specific set of expertise ought to be developed and focused on clinical development." - Gordon McCauley

Newsflash!

To view Releases highlight & left click on the company name!